EcoDrugPlus

Glutamate Ionotropic Receptor Kainate Type Subunit 4

Ensembl ID : ENSSTUG00000016958
Gene Symbol: GRIK4
3 Cross references
244 Possible Orthologues:

Glutamate Ionotropic Receptor Kainate Type Subunit 4

Ensembl ID : ENSSTUG00000004723
Gene Symbol: GRIK4
3 Cross references
244 Possible Orthologues:

Glutamate Ionotropic Receptor Kainate Type Subunit 4

Ensembl ID : ENSSTUG00000038662
Gene Symbol: GRIK4
3 Cross references
188 Possible Orthologues:

Glutamate Ionotropic Receptor Kainate Type Subunit 5

Ensembl ID : ENSSTUG00000032667
Gene Symbol: GRIK5
3 Cross references
227 Possible Orthologues:

Glutamate Ionotropic Receptor Kainate Type Subunit 5

Ensembl ID : ENSSTUG00000024354
Gene Symbol: GRIK5
3 Cross references
223 Possible Orthologues:

Glutamate Ionotropic Receptor Kainate Type Subunit 5

Ensembl ID : ENSSTUG00000038580
Gene Symbol: GRIK5
3 Cross references
227 Possible Orthologues:

Glutamate Ionotropic Receptor Kainate Type Subunit 5

Ensembl ID : ENSSTUG00000023338
Gene Symbol: GRIK5
3 Cross references
222 Possible Orthologues:

Glutamate Metabotropic Receptor 2

Ensembl ID : ENSSTUG00000017835
Gene Symbol: GRM2
3 Cross references
201 Possible Orthologues:

Glutamate Metabotropic Receptor 2

Ensembl ID : ENSSTUG00000033947
Gene Symbol: GRM2
3 Cross references
201 Possible Orthologues:

Glutamate Metabotropic Receptor 4

Ensembl ID : ENSSTUG00000018468
Gene Symbol: GRM4
3 Cross references
203 Possible Orthologues:

Glutamate Metabotropic Receptor 4

Ensembl ID : ENSSTUG00000033384
Gene Symbol: GRM4
1 Cross references
190 Possible Orthologues:

Glutamate Metabotropic Receptor 4

Ensembl ID : ENSSTUG00000038163
Gene Symbol: GRM4
3 Cross references
190 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).